BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28045731)

  • 1. 18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
    Garcia JR; Pérez C; Bassa P; Capdevila L; Ramos F; Valenti V
    Clin Nucl Med; 2017 Mar; 42(3):191-192. PubMed ID: 28045731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
    Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
    Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT with
    Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
    Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
    J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
    Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
    Correa PD; Shrimali RK; Han S; Rizwanullah M
    BMJ Case Rep; 2010 May; 2010():. PubMed ID: 22736731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and Adjuvant Therapies for Breast Cancer.
    Apuri S
    South Med J; 2017 Oct; 110(10):638-642. PubMed ID: 28973704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY; Kim SK; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Park IH; Lee KS; Shin KH; Lee S; Kim SW; Kang HS; Ro J
    Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.